NewsBenzinga리어링크 파트너스, 할로자임 테라퓨틱스 투자의견 ‘시장수익률’로 하향 조정, 목표주가 117달러로 상향 리어링크 파트너스, 할로자임 테라퓨틱스 투자의견 ‘시장수익률’로 하향 조정, 목표주가 117달러로 상향 Benzinga 2026.11.07 00:51 (GMT+0) Open on Benzinga Other news Ladenburg Thalmann Maintains Buy on MGE Energy, Raises Price Target to $86.5 Telsey Advisory Group Maintains Outperform on Steven Madden, Lowers Price Target to $50 Telsey Advisory Group Maintains Market Perform on Arhaus, Raises Price Target to $14 Telsey Advisory Group Maintains Outperform on Holley, Lowers Price Target to $4 Telsey Advisory Group Maintains Outperform on Westrock Coffee, Raises Price Target to $13 Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117
